Saracatinib is an efficacious clinical candidate for fibrodysplasia ossificans progressiva

Currently, no effective therapies exist for fibrodysplasia ossificans progressiva (FOP), a rare congenital syndrome in which heterotopic bone is formed in soft tissues owing to dysregulated activity of the bone morphogenetic protein (BMP) receptor kinase ALK2 (also known as ACVR1). From a screen of...

Descripción completa

Detalles Bibliográficos
Autores principales: Williams, Eleanor, Bagarova, Jana, Kerr, Georgina, Xia, Dong-Dong, Place, Elsie S., Dey, Devaveena, Shen, Yue, Bocobo, Geoffrey A., Mohedas, Agustin H., Huang, Xiuli, Sanderson, Philip E., Lee, Arthur, Zheng, Wei, Economides, Aris N., Smith, James C., Yu, Paul B., Bullock, Alex N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8119212/
https://www.ncbi.nlm.nih.gov/pubmed/33705358
http://dx.doi.org/10.1172/jci.insight.95042

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8119212/
https://www.ncbi.nlm.nih.gov/pubmed/33705358
http://dx.doi.org/10.1172/jci.insight.95042

Ejemplares similares